Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · December 23, 2022

Mirabegron Treatment for Chronic Pulmonary Hypertension Associated With Heart Failure

European Journal of Heart Failure


Additional Info

European Journal of Heart Failure
β3 adrenergic agonist treatment in chronic pulmonary hypertension associated with heart failure (SPHERE-HF): a double blind, placebo-controlled, randomized clinical trial
Eur. J. Heart Fail 2022 Nov 20;[EPub Ahead of Print], A García-Álvarez, I Blanco, I García-Lunar, P Jordà, JJ Rodriguez-Arias, L Fernández-Friera, I Zegri, J Nuche, M Gomez-Bueno, S Prat, S Pujadas, E Sole-Gonzalez, MD Garcia-Cossio, M Rivas, E Torrecilla, D Pereda, J Sanchez, P García-Pavía, J Segovia-Cubero, JF Delgado, S Mirabet, V Fuster, JA Barberá, B Ibañez

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading